TP53 and neoplasm: Pre-clinical study showed that treatment with a combination of alrizomadlin and anti-PD-1 in mice was able to elicit anti-tumor activity with increased efficiency than anti-PD-1 alone and is irrespective of TP53 mutation status [147].